Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CDKN2A |
Variant | D74Tfs*72 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | CDKN2A D74Tfs*72 indicates a shift in the reading frame starting at amino acid 74 and terminating 72 residues downstream causing a premature truncation of the 156 amino acid Cdkn2a protein (UniProt.org). D74Tfs*72 has not been characterized, however, due to the effects of other truncation mutations downstream of D74 (PMID: 9053859, PMID: 8668202), is predicted to lead to a loss of Cdkn2a protein function. |
Associated Drug Resistance | |
Category Variants Paths |
CDKN2A mutant CDKN2A inact mut CDKN2A D74Tfs*72 |
Transcript | NM_000077.5 |
gDNA | chr9:g.21971139delC |
cDNA | c.220delG |
Protein | p.D74Tfs*72 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001195132.2 | chr9:g.21971139delC | c.220delG | p.D74Tfs*72 | RefSeq | GRCh38/hg38 |
NM_000077.5 | chr9:g.21971139delC | c.220delG | p.D74Tfs*72 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A D74Tfs*72 | lung squamous cell carcinoma | sensitive | Carboplatin + Paclitaxel + Palbociclib | Preclinical - Pdx | Actionable | In a preclinical study, the addition of Ibrance (palbociclib) to treatment with the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved tumor growth inhibition compared to chemotherapy or Ibrance (palbociclib) alone in a patient-derived xenograft (PDX) model of squamous non-small cell lung cancer harboring CDKN2A D74Tfs*72 (PMID: 39199558). | 39199558 |